Clinuvel Pharmaceuticals (ASX:CUV) said it is in talks with the European Medicines Agency (EMA) to increase the recommended maximum dose of its drug Scenesse for adult patients with erythropoietic protoporphyria (EPP), according to a Wednesday filing with the Australian bourse.
EPP is an inherited condition characterized by extreme photosensitivity and could lead to liver disease.
The EMA's Pharmacovigilance Risk Assessment Committee will decide whether to maintain the existing drug label or expand it to up to six times per year, the filing said.
The outcome is expected by the first quarter of 2025, according to the filing.
Clinuvel Pharmaceuticals' shares were down more than 2% in recent Wednesday trade.
Price (AUD): $13.30, Change: $-0.32, Percent Change: -2.39%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。